Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen Long-term Safety Follow-up in Patients With Spinal Muscular Atrophy (Japan Extension of NCT03070119)
jRCT2080225019Phase 3Completed
- Sponsor
- Biogen
- Start
- Jan 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoint: Incidence of adverse events and serious adverse events. Started Jan 2020; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on jRCT2080225019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225019.